Ventricular fibrillation, an uncontrolled arrhythmia seeking new targets

Drug Development Research

Volumn 55, Issue 1, 2002, Pages 45-52

  Beatch, Gregory N ^a   Barrett, Terrance D ^a   Plouvier, Bertrand ^b   Jung, Grace ^b   Wall, Richard A ^a   Zolotoy, Alexander ^b   Walker, Michael J A ^a  

^a Cardiome Pharma Corp   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antiarrhythmic drug; Fibrillation; Ion channel; Ischemia; Proarrhythmia

Indexed keywords

1 (2 BUTYL 3 BENZOFURANYL) 1 [5 [2 (DIETHYLAMINO)ETHOXY] 2 THIENYL]METHANONE; 1 (3,4 DIHYDRO 4 ISOPROPYL 2,2 DIMETHYL 3 OXO 2H 1,4 BENZOXAZINE 6 CARBONYL)GUANIDINE; 2 [2 [4 (4 NITROBENZYLOXY)PHENYL]ETHYL]ISOTHIOUREA METHANESULFONATE; 5 CHLORO 4 [3 [N [2 (3,4 DIMETHOXYPHENYL)ETHYL] N METHYLAMINO]PROPYLAMINO] 3(2H) PYRIDAZINONE; [8 (2 METHOXYETHOXY) 2 PHENYL 4 QUINOLINYLCARBONYL]GUANIDINE; AMIODARONE; ANTIARRHYTHMIC AGENT; ATI 2001; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARIPORIDE; CLAMIKALANT; DOFETILIDE; DRONEDARONE; ENIPORIDE; FLECAINIDE; GYKI 16638; H 345 52; LIDOCAINE; N (3,4 DIMETHOXYPHENYL) N [3 [N [2 (3,4 DIMETHOXYPHENYL)ETHYL] N METHYLAMINO]PROPYL] 4 NITROBENZAMIDE; N [3 [[2 (3,4 DIMETHOXYPHENYL)ETHYL]AMINO]PROPYL] 4 NITROBENZAMIDE; N [3 HYDROXY 2,2 DIMETHYL 6 (4,4,4 TRIFLUOROBUTOXY)CHROMAN 4 YL] N METHYLMETHANESULFONAMIDE; POTASSIUM CHANNEL BLOCKING AGENT; PROTEIN INHIBITOR; QUINIDINE; RSD 1108; RSD 1235; SL 59 1227; SOTALOL; TEDISAMIL; TY 12533; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HUMAN; MORTALITY; NONHUMAN; PROTON SODIUM EXCHANGE; REVIEW; RISK BENEFIT ANALYSIS; SODIUM CALCIUM EXCHANGE; SURVIVAL RATE; TORSADE DES POINTES; TREATMENT OUTCOME;

EID: 0036217664     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10038     Document Type: Review

References (65)

1. Cardioprotective effect of TY-12533, a novel Na(+)/H(+) exchange inhibitor, on ischemia/reperfusion injury
2. Dofetilide: A new class III antiarrhythmic agent
3. Potassium and calcium current blocking properties of the novel antiarrhythmic agent H 345/52: Implications for proarrhythmic potential
4. Rational basis for use of sodium-hydrogen exchange inhibitors in myocardial ischemia
5. Antiarrhythmic effects of cariporide, a novel Na+-H+ exchange inhibitor, on reperfusion ventricular arrhythmias in rat hearts
6. Antiarrhythmic and electrophysiological effects of GYKI-16638, a novel N-(phenoxyalkyl)-N-phenylalkylamine, in rabbits
7. Better antiarrhythmics? Development of antiarrhythmic drugs selective for ischemia-dependent arrhythmias
8. Effects of MS-a novel Na(+)-H+ exchange inhibitor, on the myocardial infarct size in rats after postischemic administration
9. Lack of selectivity for ventricular and ischemic tissue limits the antiarrhythmic actions of lidocaine, quinidine and flecainide against ischemia-induced arrhythmias
10. Ischemia selectivity confers efficacy for suppression of ischemia-induced arrhythmias in rats
11. Antiarrhythmic properties of tedisamil (KC8857), a putative transient outward K+ current blocker
12. HMR 1883, a novel cardioselective inhibitor of the ATP-sensitive potassium channel. Part II: Effects on susceptibility to ventricular fibrillation induced by myocardial ischemia in conscious dogs
13. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: Experimental profile of BRL-32872
14. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT
15. Cariporide Aventis
16. Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias
17. Meta-analysis of antiarrhythmic drug trials
18. Tedisamil: Master switch of nature?
19. E 047/1: A new class III antiarrhythmic agent
20. Tedisamil blocks the transient and delayed rectifier K+ currents in mammalian cardiac and glial cells
21. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial
22. Inhibition of Na+/Ca2+ exchange by KB-R7943: Transport mode selectivity and antiarrhythmic consequences
23. Cardioselective K(ATP) channel blockers derived from a new series of m-anisamidoethylbenzenesulfonylthioureas
24. Tedisamil (Solvay)
25. pH-dependent blocking actions of three novel antiarrhythmic compounds on K+ and Na+ currents in rat ventricular myocytes
26. Inhibition of IKs channels by HMR 1556
27. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT
28. Azimilide dihydrochloride, a novel antiarrhythmic agent
29. Pharmacology and clinical assessment of cariporide for the treatment coronary artery diseases
30. Antiarrhythmic Effects of Na-H Exchange Inhibition
31. Molecular and cellular mechanisms of cardiac arrhythmias
32. Effects of a novel cardioprotective drug, JTV-519, on membrane currents of guinea pig ventricular myocytes
33. Effects of EGIS-7229 (S 21407), a novel class III antiarrhythmic drug, on myocardial refractoriness to electrical stimulation in vivo and in vitro
34. The anti-arrhythmia and pro-arrhythmia properties of sigma-receptor ligands
35. Pharmacological profile of SL 59.1227, a novel inhibitor of the sodium/hydrogen exchanger
36. ++-overload inhibitor, protects against aconitine-induced cardiac arrhythmias in vivo
37. Inhibition by a novel anti-arrhythmic agent, NIP-142, of cloned human cardiac K+ channel Kv1.5 current
38. Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: A placebo-controlled, implantable cardioverter-defibrillator-based evaluation
39. Quinidine-related mortality in the short-to-medium-term treatment of venticular arrhythmias. A meta-analysis
40. Effects of a selective inhibitor of Na+/Ca2+ exchange, KB-R7943, on reoxygenation-induced injuries in guinea pig papillary muscles
41. Cardiac chloride channels: Physiology, pharmacology and approaches for identifying novel modulators of activity
42. Synthesis, electrophysiological properties and analysis of structural requirements of a novel class of antiarrhythmic agents with potassium and calcium channel blocking properties
43. Inhibitory effects of JTV-519, a novel cardioprotective drug, on potassium currents and experimental atrial fibrillation in guinea-pig hearts
44. RSD1235: A novel antiarrhythmic agent with a unique electrophysiological profile that terminates AF in dogs
45. Electrophysiological effects of EGIS-7229, a new antiarrhythmic agent, in isolated mammalian and human cardiac tissues
46. Electrophysiological effects of a novel, short-acting and potent ester derivative of amiodarone, ATI-2001, in guinea pig isolated heart
47. Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT(4) receptor antagonist RS100302 in experimental atrial flutter and fibrillation
48. Dofetilide, a novel class III antiarrhythmic agent
49. Data-driven decisions: The importance of clinical trials in arrhythmia management
50. Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide
51. Identification of a peptide toxin from Grammostola spatulata spider venom that blocks cation-selective stretch-activated channels
52. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: Comparison with amiodarone
53. The Sicilian Gambit: A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms
54. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials
55. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial
56. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
57. Effect of d-sotolol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction
58. Effect of Na+/Ca2+ exchange inhibitor, KB-R7943 on ouabain-induced arrhythmias in guinea-pigs
59. Role of ATP-sensitive K+ channel current in ischemic arrhythmias
60. ATP-sensitive potassium channel blocker HMR 1883 reduces mortality and ischemia-associated electrocardiographic changes in pigs with coronary occlusion
61. Stereoselective interactions of the enantiomers of chromanol 293B with human voltage-gated potassium channels
62. The sodium-calcium ion membrane exchanger: Physiologic significance and pharmacologic implications
63. RSD1000: A novel antiarrhythmic agent with increased potency under acidic and high-potassium conditions
64. The Na+/H+ exchange inhibitor Eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the ESCAMI trial